You just read:

Veloxis Announces Submission of Marketing Authorization Application (MAA) to European Medicines Agency (EMA) for LCP-Tacro™ for Treatment of Kidney Transplant Patients

News provided by

Veloxis Pharmaceuticals

Apr 29, 2013, 07:49 ET